Pharmacologically, the importance of MHC as a target for immunodrugs has been widely assessed [11], and recently, many works reported the use of partial MHC constructs as modulators of T cells and CD74 signaling and, thus, neuroprotective agents in stroke [12,13,14,15,16]. This evidence concerns the gene HLA-C and stroke disorder.